Close
Xylem
Novotech

Press Releases

BeiGene Announces BRUKINSA Approved for Treatment of Patients with Mantle Cell Lymphoma

BeiGene, a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide,ย  announced that BRUKINSAยฎ (zanubrutinib) has been approved in Australia for the treatment of adult patients with mantle...

Etihad Cargo Expands its African Footprint with the Signing of Pharma Agreement with Astral Aviation and Kenya Airways

Etihad Cargo, the cargo and logistics arm of Abu Dhabiโ€™s Etihad Aviation Group, has expanded its pharma sector reach into Africa with the signing of a Service Legal Agreement (SLA) with Astral Aviation and Kenya Airways to provide reliable...

Enzolytics and Samsung Biologics Announce Development and Manufacturing Agreement for Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibody Therapies

Samsung Biologics , a leading contract development and manufacturing organization and Enzolytics (ENZC), a drug development company committed to commercializing multiple proprietary therapeutics to treat debilitating infectious diseases, announced the signing of a strategic CDMO partnership agreement. Under the terms...

Syntegon and Vetter win PDA Drug Delivery Innovation Award for Versynta microBatch

Together with Vetter, an international pharmaceutical service provider for injectables, Syntegon (formerly Bosch Packaging Technology) has won the PDA Drug Delivery Innovation Award. In the "Partnership Innovation" category, the Parental Drug Association (PDA) honors development projects by pharmaceutical and...

CTI BioPharma Announces Topline Data from Final Analysis of the PRE-VENT Clinical Trial Evaluating Pacritinib as a Treatment for Severe COVID-19

CTI BioPharma Corp announced topline results from the PRE-VENT trial (NCT04404361) of pacritinib in hospitalized patients with severe COVID-19. PRE-VENT, a randomized, double-blind, placebo-controlled multicenter study, compared pacritinib/standard of care versus placebo/standard of care in hospitalized patients with severe...

Moderna Announces European Medicines Agency Authorizes Third Dose of COVID-19 Vaccine for Immunocompromised Individuals Aged 12 Years and Older

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines announced that the European Medicines Agency (EMA) has authorized a third dose of the Moderna COVID-19 vaccine (Spikevax) given at least 28 days after the second dose...

TriLink BioTechnologies Extends EyeGene Partnership for COVID-19 Vaccine Development in South Korea

TriLink BioTechnologies, a Maravai LifeSciences company and a leader in the production of nucleic acids for research, diagnostics and therapeutics applications, announced that it expects to supply its proprietary CleanCapยฎ mRNA capping technology and the modified nucleoside, uridine triphosphate,...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate ยป